Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00739817|
Recruitment Status : Unknown
Verified August 2009 by Ziv Hospital.
Recruitment status was: Not yet recruiting
First Posted : August 22, 2008
Last Update Posted : August 18, 2009
Background: Primary ciliary dyskinesia (PCD) is a rare genetic disease characterised by recurrent respiratory infections and subfertility due to dysfunction of cilia (brushes) of the lining cells. Undiagnosed and untreated it can result in an irreversible crippling chronic lung disease. The diagnosis of PCD is a difficult one and involves the complex assessment of ciliary structure and function. Thus, PCD is under diagnosed and appropriate preventative and symptomatic treatment may be denied in many patients. In addition, the gene responsible for PCD is at present unknown, thus preventing pre-natal diagnosis and genetic counseling.
Working hypothesis and aims: Recently, it has become apparent that the evaluation of nasally expired nitric oxide (NO) constitutes a simple and non-invasive diagnostic method, which discriminates between PCD patients, PCD carriers and healthy controls at high rate of specificity and sensitivity. Testing is simple and last approximately one minute. We have recently identified a unique isolated Druze population with high prevalence of PCD. The high frequency of disease places this closed community at a high risk of undiagnosed PCD.
The aim of this project is to use nasal NO measurement as a screening tool to identify possible undiagnosed cases of PCD and PCD carriers in this high risk Druze population.
|Condition or disease|
|Primary Ciliary Dyskinesia|
|Study Type :||Observational|
|Estimated Enrollment :||6000 participants|
|Official Title:||Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide|
|Study Start Date :||July 2010|
- Nasal NO < 105 ppb [ Time Frame: at enrollment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00739817
|Contact: Israel Amirav, MDemail@example.com|
|Pediatric Department, Ziv Medical Center||Not yet recruiting|
|Contact: Israel Amirav, MD 9726828712 firstname.lastname@example.org|